Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 3Papillomavirus Infections 3Hepatitis B 1

Interventions

entecavir 4Lamivudine 4Sorafenib 2polysaccharide MGN3 1navitoclax 1lens intermediate filament proteins 1human papillomavirus vaccine, L1 type 16, 18 1hepatitis B hyperimmune globulin 1adefovir dipivoxil 1Tumor Necrosis Factor-alpha 1Tetanus Toxoid 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Radiofrequency Ablation 1Polymorphism, Genetic 1Pneumococcal Vaccines 1Pharmaceutical Preparations 1PHY 906 1Measles-Mumps-Rubella Vaccine 1Heptavalent Pneumococcal Conjugate Vaccine 1Hepatitis B Vaccines 1Enzyme-Linked Immunosorbent Assay 1Engerix-B 1Control Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hepatitis B × Engerix-B × Clear all
NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

GlaxoSmithKline

Phase 3 Completed
152 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡